At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 5, 2026 at 07:30 ET
CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net income, a turnaround from a $17.9M loss in 2024. Growth was fueled by DefenCath sales and the full-quarter contribution from the Melinta acquisition. The company reiterated 2026 guidance and announced a $75M share repurchase program.
- Q4 2025 net revenue was $128.6 million, up 312% from $31.2 million in Q4 2024
- Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million including Melinta
- Q4 2025 net income was $14.0 million ($0.16 diluted EPS), compared to $13.5 million ($0.20 diluted EPS) in Q4 2024
- Full-year 2025 net income was $163.1 million ($2.04 diluted EPS), versus a $17.9 million loss in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access